Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 2012

View Archived Issues

Intellect Neurosciences and iNovacia enter research service agreement

Circassia begins phase III ToleroMune trial in cat allergy

Empagliflozin has beneficial effects on blood pressure

U.S. Navy to investigate Oxygen Biotherapeutics' Oxycyte wound therapy

Updated study results on orteronel in prostate cancer presented

Preclinical profile of the prostate cancer vaccine candidate AEZS-120

Mirabegron safe in male patients with bladder outlet obstruction

Patient recruitment completed in two phase III Afrezza trials

Deciphera Pharmaceuticals announces transition to oncology drug development

National Institute of Biomedical Innovation patents new antibodies for cancer

Allergan presents new FPRL1 receptor ligands

Novel agents for diabetes prepared by Danish group

Industrial Research and University of Liverpool disclose novel BACE1 inhibitors

Locus Pharmaceuticals patents new ITK inhibitors

Researchers in Thailand synthesize novel dihydrofolate reductase inhibitors

DVS-603 improves psoriasis symptoms

Takeda aims to expand vaccine pipeline with acquisition

Chugai files application for approval of Avastin in additional indication in Japan

XenoPort discloses encouraging results from phase I trial of fumaric acid ester compound

MAA for ceftobiprole in pneumonia accepted for review under E.U. decentralized procedure

NICE publishes new draft guidance on ranibizumab for DME

The Medicines Company voluntarily discontinues development of MDCO-2010

Cempra reports topline results from phase II trial in urogenital gonorrhea

EMA accepts masitinib MAA for review

Zeria discontinues development of product candidate for allergic rhinitis

4-Antibody receives additional milestone payments from HGS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...